RIQAS Serology – Chagas Programme
RIQAS Serology – Chagas Programme
RIQAS Chagas EQA Programme – Cycle Starts March 2025
The RIQAS Serology – Chagas EQA Programme will run at the frequency of one challenge monthly, across a 12-month period. The samples will be supplied in a convenient liquid ready-to-use format requiring minimal preparation.
By providing carefully selected samples with Trypanosoma cruzi antibodies, the RIQAS Chagas Programme is designed to monitor a laboratory’s ability to correctly identify positive samples.
- 100% human material.
- Conveniently supplied in a liquid ready-to-use format.
- Comprehensive yet easy to interpret results.
- Report turnaround time of less than 72-hours.
- Frequent reporting, allowing early identification of system errors.
- Qualitative and Quantitative analysis provided.
- Meaningful comparisons with the largest international EQA scheme.
- Cycle Starts – March 2025.
Not accredited to ISO 17043
Cat No | Kit Size | Frequency | Parameters | |
---|---|---|---|---|
RQ9208 | 12 x 1ml | Monthly | 1 parameter | |
Parameter
Trypanosoma cruzi antibodies
Related Products
Chagas disease, also known as American trypanosomiasis, is a zoonotic disease caused by the single-celled parasite Trypanosoma cruzi. Chagas is most common in Latin America, but the relocation of infected individuals is causing prevalence in other countries to rise. If untreated, it can result in lifelong infection with up to 30% of infected individuals developing cardiac or gastrointestinal complications.
Screening is crucial to stop the spread of infection through blood transfusions and organ transplants, and it helps in identifying and providing treatment to people infected with the disease globally.